Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ASTX-660||ASTX660|ASTX 660||SMAC Mimetic 8||ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||ASTX-660||Preclinical - Cell line xenograft||Actionable||In a preclinical study, ASTX-660 inhibited growth of triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (Cancer Res 2016;76(14 Suppl):Abstract nr 1287).||detail...|
|Unknown unknown||Advanced Solid Tumor||not applicable||ASTX-660||Phase I||Actionable||In a Phase I trial, ASTX660 treatment was well-tolerated, and resulted in no objective responses in heavily pretreated advanced solid tumor (n=43) and lymphoma (n=2) patients with stable disease as the best response in 29% (10/35) of evaluable patients, and a median progression-free survival of 55 days and median overall survival of 265 days in the entire cohort, and clinical improvement in a patient with cutaneous T-cell lymphoma (PMID: 31900279; NCT02503423).||31900279|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04155580||Phase I||ASTX-660 ASTX-660 + ASTX727||A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)||Recruiting|
|NCT02503423||Phase Ib/II||ASTX-660||Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas||Recruiting|